SCHEMBL24256523

SCHEMBL24256523

O=C1OCCN1[C@@H]1COC(COCc2ccccc2)C(OCc2ccccc2)C1OCc1ccccc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HTR1A P08908 1/20 0.39
▸ NAAA Q02083 1/20 0.39
▸ BCHE P06276 2/20 0.38
▸ ACHE P22303 2/20 0.38
▸ FAAH O00519 2/20 0.38
▸ CA1 P00915 1/20 0.37
▸ CA2 P00918 1/20 0.37
▸ CA9 Q16790 1/20 0.37
▸ NT5E P21589 1/20 0.37
▸ TAAR1 Q96RJ0 1/20 0.36
▸ LMNA P02545 1/20 0.36
▸ PTPN1 P18031 5/20 0.35
▸ CDC25B P30305 5/20 0.35
▸ PTPN2 P17706 2/20 0.35
▸ PTPN6 P29350 2/20 0.35
▸ PTPN11 Q06124 2/20 0.35
▸ CTSV O60911 1/20 0.35
▸ CTSL P07711 1/20 0.35
▸ CTSB P07858 1/20 0.35
▸ CTSS P25774 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24256368 0.85 BCHE (0.41) HTR1ABCHEACHECA1CA2
SCHEMBL26879283 0.82 NAAA (0.38) NAAABCHEFAAHCTSVCTSL
SCHEMBL26900838 0.80 BCHE (0.43) HTR1ABCHEACHECA1CA2
SCHEMBL26900879 0.80 BCHE (0.44) HTR1ABCHEACHECA1CA2
SCHEMBL26900837 0.80 BCHE (0.43) HTR1ABCHEACHECA1CA2
SCHEMBL24256520 0.80 HTR1A (0.41) HTR1ABCHEACHECA1CA2
SCHEMBL24256721 0.80 BCHE (0.44) HTR1ABCHEACHECA1CA2
SCHEMBL23705260 0.80 HTR1A (0.41) HTR1ABCHEACHECA1CA2
SCHEMBL26900842 0.80 HTR1A (0.41) HTR1ABCHEACHECA1CA2
SCHEMBL30980710 0.80 MAOA (0.38) HTR1ABCHEACHECA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240072809-A1 ASGPR-BINDING COMPOUNDS FOR THE DEGRADATION OF EXTRACELLULAR PROTEINS AVILAR THERAPEUTICS, INC. (US) 2024-02-29 — — US disclosed
US-11819551-B2 ASGPR-binding compounds for the degradation of extracellular proteins AVILAR THERAPEUTICS, INC. (US) 2023-11-21 — — US disclosed
WO-2022035997-A1 IN VIVO ASSEMBLY OF ASGPR BINDING THERAPEUTICS AVILAR THERAPEUTICS, INC. (US) 2022-02-17 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11819551-B2 ASGPR-binding compounds for the degradation of extracellular proteins ASGR1, ENGASE, FCGR2A HTR1A 3660/4885NAAA 2212/4885BCHE 2461/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback